
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE5339B18AF323630539B10033AA5DD9.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="eurjmedres">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366048/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="European Journal of Medical Research">
<meta name="citation_title" content="The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis">
<meta name="citation_author" content="Jia-Jun Cheng">
<meta name="citation_author_institution" content="Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041 Sichuan China">
<meta name="citation_author" content="Fu-Qiang Wang">
<meta name="citation_author_institution" content="Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041 Sichuan China">
<meta name="citation_author" content="Zhang-Yi Dai">
<meta name="citation_author_institution" content="Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041 Sichuan China">
<meta name="citation_author" content="Xin-Wei Wang">
<meta name="citation_author_institution" content="Schulich School of Medicine and Dentistry, Western University, London, ON Canada">
<meta name="citation_author" content="Yun Wang">
<meta name="citation_author_institution" content="Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041 Sichuan China">
<meta name="citation_publication_date" content="2025 Aug 20">
<meta name="citation_volume" content="30">
<meta name="citation_firstpage" content="775">
<meta name="citation_doi" content="10.1186/s40001-025-03057-6">
<meta name="citation_pmid" content="40830529">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366048/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366048/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366048/pdf/40001_2025_Article_3057.pdf">
<meta name="description" content="Myasthenia gravis (MG) is a chronic autoimmune disorder affecting the neuromuscular junction, where autoreactive immunoglobulin G (IgG) plays a key role in disease pathogenesis. The novel biologic Efgartigimod is a neonatal Fc receptor (FcRn) ...">
<meta name="og:title" content="The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Myasthenia gravis (MG) is a chronic autoimmune disorder affecting the neuromuscular junction, where autoreactive immunoglobulin G (IgG) plays a key role in disease pathogenesis. The novel biologic Efgartigimod is a neonatal Fc receptor (FcRn) ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366048/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12366048">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s40001-025-03057-6"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/40001_2025_Article_3057.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366048%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12366048/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12366048/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366048/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-eurjmedres.png" alt="European Journal of Medical Research logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to European Journal of Medical Research" title="Link to European Journal of Medical Research" shape="default" href="https://eurjmedres.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Eur J Med Res</button></div>. 2025 Aug 20;30:775. doi: <a href="https://doi.org/10.1186/s40001-025-03057-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s40001-025-03057-6</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Eur%20J%20Med%20Res%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Eur%20J%20Med%20Res%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Eur%20J%20Med%20Res%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Eur%20J%20Med%20Res%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cheng%20JJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Jia-Jun Cheng</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Jia-Jun Cheng</span></h3>
<div class="p">
<sup>1</sup>Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041 Sichuan China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cheng%20JJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Jia-Jun Cheng</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20FQ%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Fu-Qiang Wang</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Fu-Qiang Wang</span></h3>
<div class="p">
<sup>1</sup>Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041 Sichuan China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20FQ%22%5BAuthor%5D" class="usa-link"><span class="name western">Fu-Qiang Wang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dai%20ZY%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Zhang-Yi Dai</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Zhang-Yi Dai</span></h3>
<div class="p">
<sup>1</sup>Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041 Sichuan China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dai%20ZY%22%5BAuthor%5D" class="usa-link"><span class="name western">Zhang-Yi Dai</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20XW%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Xin-Wei Wang</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Xin-Wei Wang</span></h3>
<div class="p">
<sup>2</sup>Schulich School of Medicine and Dentistry, Western University, London, ON Canada </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20XW%22%5BAuthor%5D" class="usa-link"><span class="name western">Xin-Wei Wang</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Yun Wang</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Yun Wang</span></h3>
<div class="p">
<sup>1</sup>Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041 Sichuan China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yun Wang</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041 Sichuan China </div>
<div id="Aff2">
<sup>2</sup>Schulich School of Medicine and Dentistry, Western University, London, ON Canada </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2024 Dec 1; Accepted 2025 Aug 12; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by-nc-nd/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12366048  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40830529/" class="usa-link">40830529</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">Myasthenia gravis (MG) is a chronic autoimmune disorder affecting the neuromuscular junction, where autoreactive immunoglobulin G (IgG) plays a key role in disease pathogenesis. The novel biologic Efgartigimod is a neonatal Fc receptor (FcRn) antagonist, promotes the lysosomal degradation of IgG, and may offer a targeted approach for managing MG. Despite the growing interest in efgartigimod, there remains a lack of comprehensive evaluation of its efficacy and safety in different MG subtypes.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">Comprehensive retrieval and screening were conducted on Pubmed, Embase, Web of Science, and Cochrane library to search studies on efgartigimod treatment. The data on response rates and adverse events were extracted, and the pooled effect size (ES) with the 95% confidence interval (CI) was calculated by fixed or random effect models. Sensitivity analysis and subgroup analysis were employed to test the heterogeneity. Funnel plots and trim-and-fill methods were used to test for publication bias.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">Data from 10 studies involving 305 patients were analyzed. The overall treatment response rate was 78% (95% CI: 67%–87%, <em>I</em><sup>2</sup> = 73.4%). Subgroup analysis revealed pooled response rates of 79.2% (95% CI: 68.5%–88.4%, <em>I</em><sup>2</sup> = 25.08%) in acetylcholine receptor antibody-positive MG (AChR+MG) patients and 76.2% (95% CI: 56.8%–91.5%, <em>I</em><sup>2</sup> = 85.95%) in group that did not differentiate auto-antibody types. The pooled incidence of adverse events was 38% (95% CI: 17%–51%, <em>I</em><sup>2</sup> = 92.59%), with infections (7%, 95% CI: 2%–14%, <em>I</em><sup>2</sup> = 62.5%), headache (7%, 95% CI: 1%–18%, <em>I</em><sup>2</sup> = 82.69%) and other (16%, 95% CI: 7%–28%, <em>I</em><sup>2</sup> = 71.81%). Among them, grade 3–4 adverse events are 1% (95% CI: 0%–2%, <em>I</em><sup>2</sup> = 0%).</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusion</h3>
<p id="Par4">Our study demonstrates that efgartigimod is highly effective and well-tolerated in patients with refractory MG. These findings suggest that efgartigimod is a promising drug for the treatment of MG.</p></section><section id="sec5"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s40001-025-03057-6.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Efgartigimod, FcRn, Myasthenia gravis, Meta-analysis, IgG</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Introduction</h2>
<p id="Par22">MG is an antibody-mediated autoimmune neuromuscular disease with complex mechanisms [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. Its pathogenesis is mainly due to autoantibodies interfering with the normal excitatory conduction process at the neuromuscular junction (NMJ), and the clinical manifestations are non-permanent hypo-muscularity of the affected muscles or muscle groups [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>,<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>]. MG patients can be divided into the following autoantibody phenotypes: (1) Acetylcholine receptor antibody-positive MG (AChR<sup>+</sup>MG), which accounts for 80–90% of cases. It is characterized by elevated levels of circulating IgG1 and IgG3 autoantibody components against AChR [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. Through complement activation, receptor inhibition, and antigenic modulation, autoantibodies impede NMJ function [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. (2) Muscle-specific kinase antibody-positive(MuSK<sup>+</sup>MG) subtype, the main component of which is IgG4 [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>,<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. (3) Low-density lipoprotein receptor-related protein 4 (LRP4) antibody [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>,<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>]. (4) Others like anti-ColQ, anti-Rapsyn, anti-Titin and anti-Cortactin antibodies [<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>–<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>].</p>
<p id="Par23">Regular management of MG includes surgical and conventional pharmacologic treatment. Patients with thymoma-associated MG and those with early-onset (&lt;50 years of age) AChR<sup>+</sup>MG are recommended to undergo thymectomy since they have a better prognosis [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. Symptomatic treatment is carried out using acetylcholinesterase inhibitors (AChEIs) to increase AChR concentrations within NMJ, thereby relieving the muscle weakness of MG patients [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. Immunosuppressive agents, particularly corticosteroids, are commonly applied for patients who have an inadequate response to AChEI treatment [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>] and exhibit a rapid onset of action and provide symptomatic relief in 80% of patients [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. Other nonsteroidal immunosuppressants comprising azathioprine, morimoto, and tacrolimus are frequently prescribed in combination with prednisone and have received favorable results in some patients [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>,<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>,<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. Nevertheless, 15% of patients still suffer from refractory MG and are faced with the challenges that their symptoms remain unimproved for a long time after receiving multiple immunosuppressants and that maintaining high drug doses brings about serious adverse reactions [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>].</p>
<p id="Par24">Neonatal Fc receptor (FcRn) is a heterodimeric glycoprotein that is extensively expressed in endothelial cells and antigen-presenting cells (APCs) [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. FcRn enhances autoimmunity by delivering IgG and antigen-antibody complexes to the APCs, which initiate T cell and B cell interactions [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>,<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. The pathogenic autoantibody IgG leads to overactive humoral immunity consequently triggering autoimmune diseases [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>,<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. AChR antibodies and MuSK antibodies are both IgG [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>,<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>]; thus, the mechanism by which FcRn antagonists block the IgG cycle can be applied to the treatment of MG. Efgartigimod is a humanized Fc fragment of IgG1 genetically engineered that displays high affinity for FcRn [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]. It is the first FDA-approved FcRn antagonist for the treatment of MG [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>,<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>].</p>
<p id="Par25">This study aims to investigate whether the efficacy and safety of real-world clinical use of efgartigimod meets expectations following the Phases II and III ADAPT trials [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>,<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]. It provides evidence-based recommendations on the efgartigimod in treatment of MG to date.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Database and search strategy</h3>
<p id="Par26">This meta-analysis complied with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline specifications [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>] and was registered with Prospero, International prospective register of systematic reviews (CRD42024595372). Literature retrieval and screen was performed independently by two investigators in five databases: Pubmed, Cochrane library, Embase, Web of Science, and Clinicaltrials.gov. The search keywords are “efgartigimod” and “myasthenia gravis”. The literature in English was searched up to September 25, 2024. Duplicate literature was excluded using Zotero software (version 7, Corporation for Digital Scholarship, USA).</p></section><section id="Sec4"><h3 class="pmc_sec_title">Eligibility criteria</h3>
<p id="Par27">Studies were considered eligible for inclusion if they met the following criteria: (1) Participants: Patients were over 18 years old, diagnosed with MG, and either unresponsive to conventional treatment or considered refractory to MG treatment. (2) Intervention: Patients were initiated on efgartigimod therapy at 10 mg/kg intravenous injection once weekly for at least one cycle (four weeks). (3) Outcomes: The primary outcome is the first cycle MG-ADL score [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>] (which assesses the severity of MG by evaluating the impact of the patient’s symptoms on daily life) response rate (reduction in MG-ADL scale score by 2 or more points over 4 weeks) and the rate of adverse events during treatment. Secondary endpoints were subgroup analyses of the literature in which patients were all AChR antibody-positive and in which patients included other subtypes of patients. (4) Study Types: Eligible studies included retrospective and prospective cohort studies, single-arm clinical trials, and randomized controlled trials (RCTs).</p>
<p id="Par28">Studies were excluded if they met any of the following criteria: (1) sample size of included patients was less than 10 patients. (2) There are no baseline data for comparing outcome indicators, such as the MG-ADL score before treatment.</p></section><section id="Sec5"><h3 class="pmc_sec_title">Data extraction and quality assessment</h3>
<p id="Par29">Two investigators (JJC and ZYD) extracted data independently, and disagreements were resolved by the third (FQW). The following data were included in each eligible literature: first author, year of study, sample size of patients, age and duration of illness, intervention, baseline change in MG-ADL scores before and after the first cycle of treatment, response rate of patients treated in the first cycle of treatment, incidence of adverse events, and type of adverse events. To assess the methodology quality of eligible studies, the Methodological Index for Non-Randomized Studies (MINORS) scale [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>] for non-randomized studies was used, with a score of 0 for not reported in the literature, 1 for reported but not detailed, and 2 for reported and detailed. Due to the inclusion of non-randomized controlled trials, only the first 8 items of the MINORS scale were assessed. The Cochrane risk of bias assessment tool was used for RCTs. The ROBINS-I (“Risk Of Bias In Non-randomized Studies of Interventions”) scale was employed to assess the risk of bias in non-RCTs [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>].</p></section><section id="Sec6"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par30">The primary outcome included in this study was the response rate after treatment, which was analyzed using STATA software (version 18, StataCorp LLC. USA) to pooled effect sizes (ES) and corresponding confidence intervals (CI). Heterogeneity within the studies was assessed using <em>I</em><sup>2</sup> statistics, When <em>I</em><sup>2</sup> &gt; 50%, it is considered that there is significant heterogeneity and a random effects model is used for analysis, otherwise, the fixed-effects model was used. We conducted the leave-one-out sensitivity test to judge the stability of the results by observing the changes in the pooled results after a single study was removed. The types of studies included were RCTs and non-RCTs and there are multiple different antibody subtypes in MG. Thus, subgroup analysis based on study types and different antibody types were used to analyze the heterogeneity of the results. Funnel plots and Egger’s test were used to evaluate the presence of publication bias. A <em>p</em> value <span xmlns:mml="http://www.w3.org/1998/Math/MathML" id="IEq1"><math id="d33e483"><mo>&lt;</mo></math></span>0.05 on Egger’s test was considered indicative of significant publication bias. The contour-enhanced funnel plot combined with the Trim-and-Fill method conducted using R studio (version 4.41 software). If there were unpublished studies that existed in the area of no statistical significance, it would indicate publication bias, and conversely the studies located in the area of statistical significance would indicate no publication bias.</p></section></section><section id="Sec7"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec8"><h3 class="pmc_sec_title">Study selection</h3>
<p id="Par31">The initial literature screening included a total of 470 articles, of which 102 from Pubmed, 146 from Embase, 148 from Web of Science, 15 from Clinicaltrails.gov, and 74 from Cochrane library are included. After self-checking by Zotero software and merging duplicates manually, 298 articles were maintained for following analysis. After reviewing titles and abstracts, 229 articles that appeared to have no direct connection to the subject were removed. The remaining 69 articles were reviewed in full text and 59 articles were disqualified due to their article category. Eventually 10 studies were included in the meta-analysis [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>,<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>,<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>–<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>] (Fig. <a href="#Fig1" class="usa-link">1</a>).</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366048_40001_2025_3057_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401d/12366048/5f8a34a0cd73/40001_2025_3057_Fig1_HTML.jpg" loading="lazy" id="MO1" height="879" width="767" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Methodology process for literature inclusion</p></figcaption></figure></section><section id="Sec9"><h3 class="pmc_sec_title">Characteristics and quality of studies</h3>
<p id="Par32">As shown in Table <a href="#Tab1" class="usa-link">1</a>, two randomized controlled trials [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>,<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>], 8 prospective and retrospective cohort studies, and single-arm clinical trials of non-randomized controlled trials comprised a total of 10 papers that were included [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>–<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]. There were 308 patients in total. Using the Cochrane Risk Assessment Tool, the outcomes of the two RCTs among the included articles are presented below. Since all biases were low risk, the results were dependable, and the included literature was of excellent quality (Supplemental Fig. <a href="#Fig1" class="usa-link">1</a>). The ROBINS-I scale shows that the included non-RCTs studies have a moderate to serious risk of bias. However, in single-arm studies, there will be a certain risk of bias due to the lack of a control group. Overall, the risk of bias is acceptable. (Supplemental Fig. <a href="#Fig2" class="usa-link">2</a>) The MINORS scale was applied to assess the quality of the 8 non-randomized controlled investigations, and the results are shown in the table below. Literature ratings varied from 12 to 15, suggesting that the included literature’s overall quality was generally of a favorable quality (Table <a href="#Tab2" class="usa-link">2</a>).
</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Characteristics of studies included</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Study</th>
<th align="left" colspan="1" rowspan="1">Year</th>
<th align="left" colspan="1" rowspan="1">Sample size</th>
<th align="left" colspan="1" rowspan="1">Age (years/SD or range)</th>
<th align="left" colspan="1" rowspan="1">Gender (female/male)</th>
<th align="left" colspan="1" rowspan="1">Duration of disease (years)</th>
<th align="left" colspan="1" rowspan="1">Intervention</th>
<th align="left" colspan="1" rowspan="1">Phenotype (AChR positive)</th>
<th align="left" colspan="1" rowspan="1">Outcome indicator</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Jie Song [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">10</td>
<td align="left" colspan="1" rowspan="1">55.50(26–76)</td>
<td align="left" colspan="1" rowspan="1">6/4</td>
<td align="left" colspan="1" rowspan="1">3.90(0–26)</td>
<td align="left" colspan="1" rowspan="1">efgartigimod IV</td>
<td align="left" colspan="1" rowspan="1">9</td>
<td align="left" colspan="1" rowspan="1">MG-ADL AE QMG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Nakul [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]</td>
<td align="left" colspan="1" rowspan="1">2023</td>
<td align="left" colspan="1" rowspan="1">37</td>
<td align="left" colspan="1" rowspan="1">65.56(14.74)</td>
<td align="left" colspan="1" rowspan="1">14/23</td>
<td align="left" colspan="1" rowspan="1">4.95(5.00)</td>
<td align="left" colspan="1" rowspan="1">efgartigimod IV</td>
<td align="left" colspan="1" rowspan="1">37</td>
<td align="left" colspan="1" rowspan="1">MG-ADL AE QMG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Remijn-Nelissen L [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">16</td>
<td align="left" colspan="1" rowspan="1">47.30(16.80)</td>
<td align="left" colspan="1" rowspan="1">11/5</td>
<td align="left" colspan="1" rowspan="1">12.00(4–17)</td>
<td align="left" colspan="1" rowspan="1">efgartigimod IV</td>
<td align="left" colspan="1" rowspan="1">16</td>
<td align="left" colspan="1" rowspan="1">MG-ADL AE QMG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Sushan [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">61</td>
<td align="left" colspan="1" rowspan="1">55.30(16.40)</td>
<td align="left" colspan="1" rowspan="1">43/18</td>
<td align="left" colspan="1" rowspan="1">5.10(8.20)</td>
<td align="left" colspan="1" rowspan="1">efgartigimod IV</td>
<td align="left" colspan="1" rowspan="1">52</td>
<td align="left" colspan="1" rowspan="1">MG-ADL AE QMG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pan Wang [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>]</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">14</td>
<td align="left" colspan="1" rowspan="1">57.70(13.30)</td>
<td align="left" colspan="1" rowspan="1">7/7</td>
<td align="left" colspan="1" rowspan="1">6.20(5.00)</td>
<td align="left" colspan="1" rowspan="1">efgartigimod IV</td>
<td align="left" colspan="1" rowspan="1">14</td>
<td align="left" colspan="1" rowspan="1">MG-ADL AE QMG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Kazuhiro [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">16</td>
<td align="left" colspan="1" rowspan="1">54.10(35–75)</td>
<td align="left" colspan="1" rowspan="1">13/3</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">efgartigimod IV</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">MG-ADL AE QMG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">suzuki [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">36</td>
<td align="left" colspan="1" rowspan="1">53.00(14.70)</td>
<td align="left" colspan="1" rowspan="1">25/11</td>
<td align="left" colspan="1" rowspan="1">12.90(14.70)</td>
<td align="left" colspan="1" rowspan="1">efgartigimod IV</td>
<td align="left" colspan="1" rowspan="1">19</td>
<td align="left" colspan="1" rowspan="1">MG-ADL AE QMG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lior [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">22</td>
<td align="left" colspan="1" rowspan="1">51.90(11–86)</td>
<td align="left" colspan="1" rowspan="1">11/11</td>
<td align="left" colspan="1" rowspan="1">6.13(0.25-20)</td>
<td align="left" colspan="1" rowspan="1">efgartigimod IV</td>
<td align="left" colspan="1" rowspan="1">22</td>
<td align="left" colspan="1" rowspan="1">MG-ADL AE QMG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">James [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>]</td>
<td align="left" colspan="1" rowspan="1">2021</td>
<td align="left" colspan="1" rowspan="1">84</td>
<td align="left" colspan="1" rowspan="1">45.90(14.40)</td>
<td align="left" colspan="1" rowspan="1">63/21</td>
<td align="left" colspan="1" rowspan="1">10.1(9.00)</td>
<td align="left" colspan="1" rowspan="1">efgartigimod IV</td>
<td align="left" colspan="1" rowspan="1">65</td>
<td align="left" colspan="1" rowspan="1">MG-ADL AE QMG</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bril [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]</td>
<td align="left" colspan="1" rowspan="1">2019</td>
<td align="left" colspan="1" rowspan="1">12</td>
<td align="left" colspan="1" rowspan="1">55.30(13.60)</td>
<td align="left" colspan="1" rowspan="1">7/5</td>
<td align="left" colspan="1" rowspan="1">8.20(9.00)</td>
<td align="left" colspan="1" rowspan="1">efgartigimod IV</td>
<td align="left" colspan="1" rowspan="1">12</td>
<td align="left" colspan="1" rowspan="1">MG-ADL AE QMG</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p19"><p><em>SD</em> Standard Deviation, <em>N/A</em> Not Applicable</p></div></div></section><figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366048_40001_2025_3057_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401d/12366048/4c7b937817eb/40001_2025_3057_Fig2_HTML.jpg" loading="lazy" id="MO2" height="327" width="767" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Pooled response rate for all literature. (ES means the pooled response rate)</p></figcaption></figure><section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Methodological Index for Non-Randomized Studies (MINORS) scale scores for each literature</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Study</th>
<th align="left" colspan="1" rowspan="1">Year</th>
<th align="left" colspan="1" rowspan="1">Research with a defined purpose</th>
<th align="left" colspan="1" rowspan="1">Patient consistency of inclusion</th>
<th align="left" colspan="1" rowspan="1">Anticipated data collection</th>
<th align="left" colspan="1" rowspan="1">Outcome indicator response study purpose</th>
<th align="left" colspan="1" rowspan="1">Objectivity of outcome indicators</th>
<th align="left" colspan="1" rowspan="1">Adequate follow-up time</th>
<th align="left" colspan="1" rowspan="1">Lost visit rate below 5%</th>
<th align="left" colspan="1" rowspan="1">Estimated sample size</th>
<th align="left" colspan="1" rowspan="1">Totals</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Jie Song [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">12</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Nakul [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]</td>
<td align="left" colspan="1" rowspan="1">2023</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">14</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Remijn-Nelissen L [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">12</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Sushan [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">15</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Pan Wang [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>]</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">13</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Kazuhiro [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">15</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Suzuki [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">14</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lior<sup><a href="#CR40" class="usa-link" aria-describedby="CR40">40</a></sup>
</td>
<td align="left" colspan="1" rowspan="1">2024</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">2</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">14</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="Sec10"><h3 class="pmc_sec_title">Treatment evaluation</h3>
<p id="Par33">Ten literatures contained 308 patients, of which 305 (one patient was excluded for discontinued treatment of efgartigimod because of <em>C. difficile</em> infection. Two patients were omitted due to insufficient information) reported baseline changes before and after the first cycle of treatment for the primary outcome indicator, and 9 literatures reported 120 adverse events [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>,<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>,<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>–<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>,<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]. The patients reported in 5 literatures were all AChR<sup>+</sup>MG [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>,<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>–<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>,<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]. (Supplemental Table 1)</p></section><section id="Sec11"><h3 class="pmc_sec_title">Response rate assessment</h3>
<p id="Par34">Ten literatures involving 305 patients reported the response rate to the first treatment cycle. The random effects model indicated that the pooled response rate is 78% (95% CI: 67%–87%, <em>I</em><sup>2</sup> = 73.40%) with significant heterogeneity observed (Fig. <a href="#Fig2" class="usa-link">2</a>). Sensitivity analyses and funnel plots are commonly applied to explore the sources of significant heterogeneity.</p></section><section id="Sec12"><h3 class="pmc_sec_title">Safety and tolerability assessment</h3>
<section id="Sec13"><h4 class="pmc_sec_title">Overall adverse reactions</h4>
<p id="Par35">Nine of the 10 included literatures reported treatment-related adverse reactions [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>,<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>,<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>–<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>,<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>], with a total of 120 adverse events occurring in 289 patients. The pooled incidence rate was 38% (95% CI: 17%–61%, <em>I</em><sup>2</sup> = 92.59%). (Fig. <a href="#Fig3" class="usa-link">3</a>)</p>
<figure class="fig xbox font-sm" id="Fig3"><h5 class="obj_head">Fig. 3.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401d/12366048/e6778878d089/40001_2025_3057_Fig3_HTML.jpg" loading="lazy" id="MO3" height="324" width="581" alt="Fig. 3"></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Overall adverse events’ incidence. (ES means the pooled incidence of the adverse event)</p></figcaption></figure></section></section><section id="Sec14"><h3 class="pmc_sec_title">Each type of AEs</h3>
<p id="Par36">Multiple infections occurred in efgartigimod-treated patients, but the vast majority of the reports were upper respiratory and urinary tract infections, with 30 infections reported in 9 publications, for a pooled incidence of 7% (95% CI: 2%–14%, <em>I</em><sup>2</sup> = 62.50%) (Fig. <a href="#Fig4" class="usa-link">4</a>A). 35 headache events were reported in 9 literatures with a pooled incidence of 7% (95% CI: 1%–18%, <em>I</em><sup>2</sup> = 82.69%) (Fig. <a href="#Fig4" class="usa-link">4</a>B). In addition to infections and headache, a total of 50 cases of mild AEs included diarrhea, nausea, malaise, sore lips, muscle stiffness, and neck rash were reported in 9 literatures, with a pooled incidence of 16% (95% CI: 7%–26%, <em>I</em><sup>2</sup> = 71.81%) (Fig. <a href="#Fig4" class="usa-link">4</a>C). In 9 literatures, two studies reported a total of 5 cases of grade 3–4 serious adverse events [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>,<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]. Among them were 1 case of myasthenia gravis crisis, 1 case of thrombocytosis, 1 case of rectal adenocarcinoma, 1 case of worsening myasthenia gravis, and 1 case of depression. The pooled incidence was 1% (95% CI: 0%–2%, <em>I</em><sup>2</sup> = 0%) (Fig. <a href="#Fig4" class="usa-link">4</a>D).</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366048_40001_2025_3057_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401d/12366048/1d5de6cc21b5/40001_2025_3057_Fig4_HTML.jpg" loading="lazy" id="MO4" height="429" width="778" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Each type of AEs. (ES means the pooled incidence of the adverse event). <strong>A</strong>: Infections (upper respiratory tract infections and urinary tract infections) <strong>B</strong>: Headache <strong>C</strong>: Other AEs <strong>D</strong>: 3–4 grade AEs</p></figcaption></figure></section><section id="Sec15"><h3 class="pmc_sec_title">Sensitivity analysis and publication bias</h3>
<p id="Par37">Sensitivity analysis demonstrated that the analysis is credible because none of the literature was able to significantly alter the 95% CI (Fig. <a href="#Fig5" class="usa-link">5</a>A). Funnel plot shows the meta-analysis’s publication bias (Fig. <a href="#Fig5" class="usa-link">5</a>B). The funnel plot’s degree of symmetry was evaluated with Egger’s test, and the result showed P=0.926, indicating that there was no discernible publication bias and that the funnel plot was symmetrical (Fig. <a href="#Fig5" class="usa-link">5</a>C). In the contour-enhanced funnel plot, the included literatures were all distributed on the right side and statistically significant, but the distribution was uneven (Fig. <a href="#Fig5" class="usa-link">5</a>D). After applying Trim-and-Fill Method, there were no studies added in the region of no statistical significance, and the funnel plot still exhibited asymmetry clustered on the right side. The results suggest that there is asymmetry in contour-enhanced funnel plots and some publication bias in this study, but the overall severity is low. (Fig. <a href="#Fig5" class="usa-link">5</a>)</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366048_40001_2025_3057_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401d/12366048/70dd81cf2e7c/40001_2025_3057_Fig5_HTML.jpg" loading="lazy" id="MO5" height="465" width="778" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Sensitivity analysis and publication bias. <strong>A</strong>: Sensitivity analysis <strong>B</strong>: Funnel plot <strong>C</strong>: Egger’s test <strong>D</strong>: Contour-enhanced funnel plot</p></figcaption></figure></section><section id="Sec16"><h3 class="pmc_sec_title">Subgroup analysis</h3>
<p id="Par38">Due to the heterogeneity in the results, we carried out subgroup analyses. The results of the subgroup analysis based on study types indicated that the differences between groups were not statistically significant (<em>P</em> = 0.314) and were not the main cause of the heterogeneity (Supplemental Fig. <a href="#Fig3" class="usa-link">3</a>). Different pathogenic antibodies in MG have diverse pathogenic mechanisms. We therefore conducted the subgroup analysis to estimate the efficiency of Efgartigimod in different types of MG. Subgroup analysis is conducted according to the autoantibodies. In 5 studies on AChR<sup>+</sup>MG [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>,<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>–<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>,<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>], pooled response rate was 79.2% (95% CI: 68.5%–88.4%, <em>I</em><sup>2</sup> = 25.080%), with <em>I</em><sup>2</sup>&lt;50% and heterogeneity was not remarkable. In the other 5 studies that did not differentiate between auto-antibody types [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>,<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>–<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>,<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>], ES was 76.2% (95% CI: 56.8%–91.5%), with significant heterogeneity (<em>I</em><sup>2</sup> = 85.949%). It is suggested that the different antibodies in studies might be a source of heterogeneity (Fig. <a href="#Fig6" class="usa-link">6</a>).</p>
<figure class="fig xbox font-sm" id="Fig6"><h4 class="obj_head">Fig. 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366048_40001_2025_3057_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401d/12366048/30e3bd85d143/40001_2025_3057_Fig6_HTML.jpg" loading="lazy" id="MO6" height="514" width="767" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Subgroup analysis of different antibody subtypes</p></figcaption></figure><p id="Par39">Subgroup analysis by study types revealed a reduced pooled effect size (ES) for RCTs compared to other study types (0.70 vs. 0.79) (Supplemental Fig. <a href="#Fig3" class="usa-link">3</a>). Consequently, we conducted a separate meta-analysis of RCTs to evaluate the efficacy and safety of efgartigimod. Under the fixed-effects model, the risk ratio (RR) for efficacy of efgartigimod versus placebo was 1.85 (95% CI: 1.38–2.46), while the RR for safety was 0.93 (95% CI: 0.81–1.07). The results demonstrate that efgartigimod exhibits significant efficacy and reliable safety in RCTs, which is consistent with the pooled ES conclusion from single-arm meta-analysis. (Fig. <a href="#Fig7" class="usa-link">7</a>)</p>
<figure class="fig xbox font-sm" id="Fig7"><h4 class="obj_head">Fig. 7.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366048_40001_2025_3057_Fig7_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/401d/12366048/13b2c1dd0359/40001_2025_3057_Fig7_HTML.jpg" loading="lazy" id="MO7" height="333" width="778" alt="Fig. 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Randomized controlled trials (RCTs) for efficacy and safety meta-analysis. <strong>A</strong>: The pooled risk ratio (RR) for the efficacy of RCTs <strong>B</strong>: The pooled risk ratio (RR) for the safety of RCTs</p></figcaption></figure></section></section><section id="Sec17"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par40">Refractory MG is insensitive to regular therapies, and simply increasing the dosage of immunosuppressive agents can lead to severe adverse events and impair the quality of life of MG patients [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>,<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]. Efgartigimod has displayed considerable therapeutic potential in the ADAPT trial [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>], but real-world efficacy and safety have not yet been demonstrated. Consequently, we gathered data related to the treatment of MG with efgartigimod for systematic review and meta-analysis to evaluate the efficacy and safety of efgartigimod in the treatment of MG.</p>
<p id="Par41">The pooled analysis of response rates across all included studies resulted in 78% (95% CI: 67%–87%, <em>I</em><sup>2</sup> = 73.40%), indicating a favorable efficacy rate for efgartigimod treatment. Pathogenic autoantibodies IgG-mediated hyperactive humoral immunity leads to autoimmune diseases. Both MuSK (IgG4) and AChR (IgG1 and IgG3) antibodies are IgG components in the antibody typing of MG, and the IgG clearance effect of efgartigimod holds good promise for targeting the etiology of MG [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>,<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]. The phase III ADAPT trial’s long-term follow-up (&gt;1 year) revealed consistent reductions in MG-ADL, QMG, IgG levels, and autoantibodies to AChR in each treatment cycle for patients with AChR<sup>+</sup>MG. These findings imply that efgartigimod has a profound long-term benefit in treating AChR<sup>+</sup>MG patients [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>,<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. Despite the distinct pathophysiology of MuSK antibody patients compared to AChR antibody patients [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>], the outcomes of multicenter treatment indicated that efgartigimod treatment proved satisfactorily effective for MuSK<sup>+</sup>MG patients as well. This suggests that efgartigimod has a similar ability to reduce the levels of IgG1, IgG3, and IgG4 [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>,<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]. The inclusion of retrospective, prospective trials and single-arm trials usually caused notable heterogeneity in the results of the analyses; however, both sensitivity analysis and funnel plots revealed that no study influenced the quality of this study.</p>
<p id="Par42">Heterogeneity in pooled response rates may be caused by variance in efgartigimod’s efficacy when treating patients with different antibody phenotypes. After performing a subgroup analysis, we discovered that heterogeneity was not remarkable in the AChR<sup>+</sup>MG group, with a pooled response rate of 79.2% (95% CI: 68.5%–88.4%, <em>I</em><sup>2</sup> = 25.080%), whereas the pooled response rate in the non- AChR<sup>+</sup>MG group was 76.2% (95% CI: 56.8%–91.5%, <em>I</em><sup>2</sup> = 85.949%) still with significant heterogeneity. The results indicate that the variability in efgartigimod efficacy can be attributed to diversity in antibody phenotypes. In the phase III ADAPT trial [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>], 68% of AChR<sup>-</sup>MG patients responded, similar to the AChR<sup>+</sup>MG group, meaning that efgartigimod has the potential to treat non- AChR<sup>+</sup>MG patients. Case reports have documented efficacious application of efgartigimod in the treatment of MuSK<sup>+</sup>MG patients [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>]. The promising therapeutic effects of efgartigimod treatment are evident despite the deficiency of data on patients with MuSK. A single-center retrospective study with 16 patients who tested negative for both AChR and MuSK antibodies concluded that efgartigimod insufficiently improve outcomes, but it did lower corticosteroid dosage and MG-ADL scale scores [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>]. We considered that individual differences among patients might result in variations in treatment outcomes. The pathogenesis of MG involves multiple molecules and proteins, such as the Argin-Lrp4-MuSK signaling pathway that regulates NMJ and the complicated cellular pathogenesis of MG [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>]. Even when patients are stereotyped as AChR<sup>+</sup>MG at diagnosis, in one study, it proved that this group of patients has the potential to be categorized into more precise subgroups [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]. Additionally, activation of nonspecific immunity is a possible pathogenic mechanism in MG, especially in viral infections (COVID-19) and thymoma-associated MG [<a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>–<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]. The majority of individuals with MG feature a substantial amount of germinal centers (GCs) that formed in the thymus as a result of the interaction between T and B cells [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>]. The primary source of autoimmune antibodies against AChR and MuSK is plasmablast, which are differentiated from mature B cells [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>]. In addition to T and B cells, a vast array of cytokines are involved in the pathogenesis of MG, such as IL-21, IL-6, IL-2, CD19, CD40, and B cell activating factor (BAFF), etc [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>,<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>]. FcRn transports not only IgG, but also antigen–antibody complexes to the APC, and the possible mechanism is to promote autoimmunity through the presentation of MHC I and II and hence activation of T cells and cellular immunity [<a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>]. The FcRn antagonist efgartigimod might possess a therapeutic effect on MG patients by inhibiting T cell and B cell interactions through this pathway, thus decreasing autoimmune levels [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>].</p>
<p id="Par43">The pooled incidence of adverse events was 38% (95% CI: 17%–51%, <em>I</em><sup>2</sup> = 92.59%). Infections (7%, 95% CI: 2%–14%, <em>I</em><sup>2</sup>=62.50%) and headache (7%, 95% CI: 1%–18%, <em>I</em><sup>2</sup>=82.69%) served as the primary adverse reactions with efgartigimod and had a low incidence. Besides other AEs (16%, 95% CI: 7%–28%, <em>I</em><sup>2</sup> = 71.81%) have symptoms that are generally mild and acceptable and do not lead to treatment interruptions. These results demonstrated that the safety and tolerability of efgartigimod are dependable. In contrast, under regular management, apart from the ineffectiveness of conventional immuno-suppressants in refractory MG, adverse events and severe side effects may accompany the entire period of use, and treatment even be interrupted as a result [<a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>,<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>]. Another evidence that testifies to the security of efgartigimod is in phase II and III trials, as well as in some real-world efgartigimod trials, it was confirmed that the IgG-scavenging effect of efgartigimod is selective and does not reduce the overall level of immunoglobulins and albumin [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>,<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]. Although there were 5 cases of grade 3–4 AE in the included literatures, the incidence was not statistically significant (<em>P</em> = 0.15). The probable reason for this is that patients with refractory MG tend to be older, have a higher burden of underlying disease, and may also suffer from other immune system disorders [<a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>,<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>]. The occurrence of grade 3–4 AEs may not be directly related to efgartigimod treatment.</p>
<p id="Par44">Our study demonstrated that “Randomized controlled trials provide evidence that a treatment works: Real-world evidence is required to assess if proven treatments are effective in practice” with rigorous methodology and authentic data while our results emphasized the superiority of efgartigimod as a therapeutic agent for MG. This study has a few limitations. First, efgartigimod is a newly approved drug, and current clinical case data on the drug are lacking. Therefore, the sample size extracted from the literature is limited, especially the number of non-AChR<sup>+</sup>MG patients. Some crucial data, such as QMG (Quantitative Myasthenia Gravis) Score, IgG and autoantibody concentrations, and serologic changes before and after dosing, were absent from the tracking. Furthermore, the primary outcome measure in our study, the MG-ADL score, demonstrates superior suitability for assessing therapeutic response and disease status in clinical trials. However, compared to other MG rating scales, such as QMG Score and Myasthenia Gravis Composite (MGC) Score, the MG-ADL exhibits a degree of subjectivity in its assessment. Second, there are deficient follow-up data on efgartigimod maintenance therapy and long-term prognosis. Our subgroup analysis also indicates the existence of subtle differences between the outcomes of RCTs and those from prospective or retrospective studies. Thus, more extensive clinic cohort studies and rigorous multicenter long-term follow-up are required to establish efgartigimod as a mature clinical drug. Lastly, the causes and mechanisms underlying the differing efficacy demonstrated by efgartigimod in treating patients with distinct antibody phenotypes and the occurrence of therapeutic side effects remain to be revealed by further in-depth studies.</p></section><section id="Sec18"><h2 class="pmc_sec_title">Conclusion</h2>
<p id="Par45">Based on its positive efficacy and safety, patients with refractory MG of all antibody subtypes ought to attempt to select efgartigimod therapy. Patients have shown improvements in clinical symptoms and quality of life, along with a reduction in the steroid dosage for maintenance medication. Meanwhile, compared with other immuno-suppressants, the adverse reactions associated with efgartigimod are more tolerable. Furthermore, more cohort studies and RCTs with rigorous research design are needed to determine efgartigimod’s long-term effects and differences in efficacy among different subtypes of MG.</p></section><section id="Sec19"><h2 class="pmc_sec_title">Supplementary Information</h2>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12366048/bin/40001_2025_3057_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Additional file1</a><sup> (872.5KB, docx) </sup>
</div></div></section></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>MG</dt>
<dd><p id="Par5">Myasthenia gravis</p></dd>
<dt>IgG</dt>
<dd><p id="Par6">Immunoglobulin G</p></dd>
<dt>FcRn</dt>
<dd><p id="Par7">Fc receptor</p></dd>
<dt>ES</dt>
<dd><p id="Par8">Effect size</p></dd>
<dt>RR</dt>
<dd><p id="Par9">Risk ratio</p></dd>
<dt>CI</dt>
<dd><p id="Par10">Confidence interval</p></dd>
<dt>AChR+MG</dt>
<dd><p id="Par11">acetylcholine receptor antibody-positive MG</p></dd>
<dt>NMJ</dt>
<dd><p id="Par12">Neuromuscular junction</p></dd>
<dt>MuSK<sup>+</sup>MG</dt>
<dd><p id="Par13">Muscle-specific kinase antibody-positive</p></dd>
<dt>LRP4</dt>
<dd><p id="Par14">Low-density lipoprotein receptor-related protein 4</p></dd>
<dt>AChEIs</dt>
<dd><p id="Par15">Acetylcholinesterase inhibitors</p></dd>
<dt>APCs</dt>
<dd><p id="Par16">Antigen-presenting cells</p></dd>
<dt>PRISMA</dt>
<dd><p id="Par17">Preferred reporting items for systematic reviews and meta-analyses</p></dd>
<dt>RCTs</dt>
<dd><p id="Par18">Randomized controlled trials</p></dd>
<dt>MINORS</dt>
<dd><p id="Par19">Methodological index for non-randomized studies</p></dd>
<dt>BAFF</dt>
<dd><p id="Par20">B cell activating factor</p></dd>
<dt>AE</dt>
<dd><p id="Par21">Adverse event</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contribution</h2>
<p>Jia-Jun Cheng, Data curation, Formal analysis, Writing original draft. Fu-Qiang Wang, Writing review and editing, methodology. Zhang-Yi Dai, Software, Visualization. Xin-Wei Wang, Data curation, Formal analysis. Yun Wang, Conceptualization, Supervision, Funding acquisition. Cheng Jia-Jun and Wang Fu-Qiang contribute equally to this work.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>This study was supported by the Key Research Project of Sichuan Province (No.2023YFS0199)</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>No datasets were generated or analysed during the current study.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics for approval and consent to participate</h3>
<p id="Par46">Since no participants have been recruited for this study, it was not subject to institutional ethical committee review. It complies with the journal’s ethical requirements.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Conflict of interest</h3>
<p id="Par47">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher's Note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. 10.1038/s41572-019-0079-y.
</cite> [<a href="https://doi.org/10.1038/s41572-019-0079-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31048702/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gilhus%20NE,%20Tzartos%20S,%20Evoli%20A,%20Palace%20J,%20Burns%20TM,%20Verschuuren%20JJGM.%20Myasthenia%20gravis.%20Nat%20Rev%20Dis%20Primers.%202019;5(1):30.%2010.1038/s41572-019-0079-y." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Jordan SJ. Jillian. Minn Rev. 2018;2018(90):7–8. 10.1215/00265667-4391153.</cite> [<a href="https://scholar.google.com/scholar_lookup?Jordan%20SJ.%20Jillian.%20Minn%20Rev.%202018;2018(90):7%E2%80%938.%2010.1215/00265667-4391153." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Paz ML, Barrantes FJ. Autoimmune attack of the neuromuscular junction in myasthenia gravis: nicotinic acetylcholine receptors and other targets. ACS Chem Neurosci. 2019. 10.1021/acschemneuro.9b00041.
</cite> [<a href="https://doi.org/10.1021/acschemneuro.9b00041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30916550/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Paz%20ML,%20Barrantes%20FJ.%20Autoimmune%20attack%20of%20the%20neuromuscular%20junction%20in%20myasthenia%20gravis:%20nicotinic%20acetylcholine%20receptors%20and%20other%20targets.%20ACS%20Chem%20Neurosci.%202019.%2010.1021/acschemneuro.9b00041." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843–54. 10.1172/JCI29894.
</cite> [<a href="https://doi.org/10.1172/JCI29894" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC1626141/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17080188/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Conti-Fine%20BM,%20Milani%20M,%20Kaminski%20HJ.%20Myasthenia%20gravis:%20past,%20present,%20and%20future.%20J%20Clin%20Invest.%202006;116(11):2843%E2%80%9354.%2010.1172/JCI29894." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Pham MC, Masi G, Patzina R, et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 2023;146(2):319–36. 10.1007/s00401-023-02603-y.
</cite> [<a href="https://doi.org/10.1007/s00401-023-02603-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11380498/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37344701/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pham%20MC,%20Masi%20G,%20Patzina%20R,%20et%20al.%20Individual%20myasthenia%20gravis%20autoantibody%20clones%20can%20efficiently%20mediate%20multiple%20mechanisms%20of%20pathology.%20Acta%20Neuropathol.%202023;146(2):319%E2%80%9336.%2010.1007/s00401-023-02603-y." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O’Connor KC. B cells in the pathophysiology of myasthenia gravis. Muscle Nerve. 2018;57(2):172–84. 10.1002/mus.25973.
</cite> [<a href="https://doi.org/10.1002/mus.25973" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5767142/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28940642/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yi%20JS,%20Guptill%20JT,%20Stathopoulos%20P,%20Nowak%20RJ,%20O%E2%80%99Connor%20KC.%20B%20cells%20in%20the%20pathophysiology%20of%20myasthenia%20gravis.%20Muscle%20Nerve.%202018;57(2):172%E2%80%9384.%2010.1002/mus.25973." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Koneczny I, Stevens JAA, De Rosa A, et al. IgG4 autoantibodies against muscle-specific kinase undergo fab-arm exchange in myasthenia gravis patients. J Autoimmun. 2017;77:104–15. 10.1016/j.jaut.2016.11.005.
</cite> [<a href="https://doi.org/10.1016/j.jaut.2016.11.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27965060/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Koneczny%20I,%20Stevens%20JAA,%20De%20Rosa%20A,%20et%20al.%20IgG4%20autoantibodies%20against%20muscle-specific%20kinase%20undergo%20fab-arm%20exchange%20in%20myasthenia%20gravis%20patients.%20J%20Autoimmun.%202017;77:104%E2%80%9315.%2010.1016/j.jaut.2016.11.005." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Kim N, Stiegler AL, Cameron TO, et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell. 2008;135(2):334–42. 10.1016/j.cell.2008.10.002.
</cite> [<a href="https://doi.org/10.1016/j.cell.2008.10.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2933840/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18848351/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kim%20N,%20Stiegler%20AL,%20Cameron%20TO,%20et%20al.%20Lrp4%20is%20a%20receptor%20for%20Agrin%20and%20forms%20a%20complex%20with%20MuSK.%20Cell.%202008;135(2):334%E2%80%9342.%2010.1016/j.cell.2008.10.002." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Rodríguez Cruz PM, Palace J, Beeson D. The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes. Int J Mol Sci. 2018;19(6):1677. 10.3390/ijms19061677.
</cite> [<a href="https://doi.org/10.3390/ijms19061677" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6032286/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29874875/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rodr%C3%ADguez%20Cruz%20PM,%20Palace%20J,%20Beeson%20D.%20The%20neuromuscular%20junction%20and%20wide%20heterogeneity%20of%20congenital%20myasthenic%20syndromes.%20Int%20J%20Mol%20Sci.%202018;19(6):1677.%2010.3390/ijms19061677." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Ohno K, Ito M, Kawakami Y, Krejci E, Engel AG. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis. Chem Biol Interact. 2013;203(1):335–40. 10.1016/j.cbi.2012.08.020.
</cite> [<a href="https://doi.org/10.1016/j.cbi.2012.08.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4405266/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22981737/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ohno%20K,%20Ito%20M,%20Kawakami%20Y,%20Krejci%20E,%20Engel%20AG.%20Specific%20binding%20of%20collagen%20Q%20to%20the%20neuromuscular%20junction%20is%20exploited%20to%20cure%20congenital%20myasthenia%20and%20to%20explore%20bases%20of%20myasthenia%20gravis.%20Chem%20Biol%20Interact.%202013;203(1):335%E2%80%9340.%2010.1016/j.cbi.2012.08.020." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Agius MA, Zhu S, Kirvan CA, et al. Rapsyn antibodies in myasthenia gravis. Ann N Y Acad Sci. 1998;841:516–21. 10.1111/j.1749-6632.1998.tb10972.x.
</cite> [<a href="https://doi.org/10.1111/j.1749-6632.1998.tb10972.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9668284/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Agius%20MA,%20Zhu%20S,%20Kirvan%20CA,%20et%20al.%20Rapsyn%20antibodies%20in%20myasthenia%20gravis.%20Ann%20N%20Y%20Acad%20Sci.%201998;841:516%E2%80%9321.%2010.1111/j.1749-6632.1998.tb10972.x." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Gallardo E, Martínez-Hernández E, Titulaer MJ, et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev. 2014;13(10):1003–7. 10.1016/j.autrev.2014.08.039.
</cite> [<a href="https://doi.org/10.1016/j.autrev.2014.08.039" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25193850/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gallardo%20E,%20Mart%C3%ADnez-Hern%C3%A1ndez%20E,%20Titulaer%20MJ,%20et%20al.%20Cortactin%20autoantibodies%20in%20myasthenia%20gravis.%20Autoimmun%20Rev.%202014;13(10):1003%E2%80%937.%2010.1016/j.autrev.2014.08.039." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis - autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12(5):259–68. 10.1038/nrneurol.2016.44.
</cite> [<a href="https://doi.org/10.1038/nrneurol.2016.44" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27103470/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gilhus%20NE,%20Skeie%20GO,%20Romi%20F,%20Lazaridis%20K,%20Zisimopoulou%20P,%20Tzartos%20S.%20Myasthenia%20gravis%20-%20autoantibody%20characteristics%20and%20their%20implications%20for%20therapy.%20Nat%20Rev%20Neurol.%202016;12(5):259%E2%80%9368.%2010.1038/nrneurol.2016.44." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Berrih-Aknin S, Le Panse R. Thymectomy in myasthenia gravis: when, why, and how? Lancet Neurol. 2019;18(3):225–6. 10.1016/S1474-4422(18)30467-8.
</cite> [<a href="https://doi.org/10.1016/S1474-4422(18)30467-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30692053/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Berrih-Aknin%20S,%20Le%20Panse%20R.%20Thymectomy%20in%20myasthenia%20gravis:%20when,%20why,%20and%20how?%20Lancet%20Neurol.%202019;18(3):225%E2%80%936.%2010.1016/S1474-4422(18)30467-8." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419–25. 10.1212/WNL.0000000000002790.
</cite> [<a href="https://doi.org/10.1212/WNL.0000000000002790" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4977114/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27358333/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sanders%20DB,%20Wolfe%20GI,%20Benatar%20M,%20et%20al.%20International%20consensus%20guidance%20for%20management%20of%20myasthenia%20gravis:%20executive%20summary.%20Neurology.%202016;87(4):419%E2%80%9325.%2010.1212/WNL.0000000000002790." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Gotterer L, Li Y. Maintenance immunosuppression in myasthenia gravis. J Neurol Sci. 2016;369:294–302. 10.1016/j.jns.2016.08.057.
</cite> [<a href="https://doi.org/10.1016/j.jns.2016.08.057" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27653912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gotterer%20L,%20Li%20Y.%20Maintenance%20immunosuppression%20in%20myasthenia%20gravis.%20J%20Neurol%20Sci.%202016;369:294%E2%80%93302.%2010.1016/j.jns.2016.08.057." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Fonseca V, Havard CW. Long term treatment of myasthenia gravis with azathioprine. Postgrad Med J. 1990;66(772):102–5. 10.1136/pgmj.66.772.102.
</cite> [<a href="https://doi.org/10.1136/pgmj.66.772.102" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2429542/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2112245/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fonseca%20V,%20Havard%20CW.%20Long%20term%20treatment%20of%20myasthenia%20gravis%20with%20azathioprine.%20Postgrad%20Med%20J.%201990;66(772):102%E2%80%935.%2010.1136/pgmj.66.772.102." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Cruz JL, Wolff ML, Vanderman AJ, Brown JN. The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord. 2015;8(2):92–103. 10.1177/1756285615571873.
</cite> [<a href="https://doi.org/10.1177/1756285615571873" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4356660/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25922621/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cruz%20JL,%20Wolff%20ML,%20Vanderman%20AJ,%20Brown%20JN.%20The%20emerging%20role%20of%20tacrolimus%20in%20myasthenia%20gravis.%20Ther%20Adv%20Neurol%20Disord.%202015;8(2):92%E2%80%93103.%2010.1177/1756285615571873." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Beecher G, Putko BN, Wagner AN, Siddiqi ZA. Therapies directed against B-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status. Drugs. 2019;79(4):353–64. 10.1007/s40265-019-1065-0.
</cite> [<a href="https://doi.org/10.1007/s40265-019-1065-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30762205/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Beecher%20G,%20Putko%20BN,%20Wagner%20AN,%20Siddiqi%20ZA.%20Therapies%20directed%20against%20B-cells%20and%20downstream%20effectors%20in%20generalized%20autoimmune%20myasthenia%20gravis:%20current%20status.%20Drugs.%202019;79(4):353%E2%80%9364.%2010.1007/s40265-019-1065-0." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Dickinson BL, Badizadegan K, Wu Z, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest. 1999;104(7):903–11. 10.1172/JCI6968.
</cite> [<a href="https://doi.org/10.1172/JCI6968" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC408555/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10510331/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dickinson%20BL,%20Badizadegan%20K,%20Wu%20Z,%20et%20al.%20Bidirectional%20FcRn-dependent%20IgG%20transport%20in%20a%20polarized%20human%20intestinal%20epithelial%20cell%20line.%20J%20Clin%20Invest.%201999;104(7):903%E2%80%9311.%2010.1172/JCI6968." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Baker K, Qiao SW, Kuo TT, et al. Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci U S A. 2011;108(24):9927–32. 10.1073/pnas.1019037108.
</cite> [<a href="https://doi.org/10.1073/pnas.1019037108" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3116387/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21628593/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Baker%20K,%20Qiao%20SW,%20Kuo%20TT,%20et%20al.%20Neonatal%20Fc%20receptor%20for%20IgG%20(FcRn)%20regulates%20cross-presentation%20of%20IgG%20immune%20complexes%20by%20CD8-CD11b+%20dendritic%20cells.%20Proc%20Natl%20Acad%20Sci%20U%20S%20A.%202011;108(24):9927%E2%80%9332.%2010.1073/pnas.1019037108." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Björck P, Beilhack A, Herman EI, Negrin RS, Engleman EG. Plasmacytoid dendritic cells take up opsonized antigen leading to CD4+ and CD8+ T cell activation <em>in vivo</em>. J Immunol. 2008;181(6):3811–7. 10.4049/jimmunol.181.6.3811.
</cite> [<a href="https://doi.org/10.4049/jimmunol.181.6.3811" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2884144/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18768834/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bj%C3%B6rck%20P,%20Beilhack%20A,%20Herman%20EI,%20Negrin%20RS,%20Engleman%20EG.%20Plasmacytoid%20dendritic%20cells%20take%20up%20opsonized%20antigen%20leading%20to%20CD4+%20and%20CD8+%20T%20cell%20activation%20in%20vivo.%20J%20Immunol.%202008;181(6):3811%E2%80%937.%2010.4049/jimmunol.181.6.3811." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Gable KL, Guptill JT. Antagonism of the neonatal Fc receptor as an emerging treatment for Myasthenia Gravis. Front Immunol. 2019;10:3052. 10.3389/fimmu.2019.03052.
</cite> [<a href="https://doi.org/10.3389/fimmu.2019.03052" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6965493/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31998320/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gable%20KL,%20Guptill%20JT.%20Antagonism%20of%20the%20neonatal%20Fc%20receptor%20as%20an%20emerging%20treatment%20for%20Myasthenia%20Gravis.%20Front%20Immunol.%202019;10:3052.%2010.3389/fimmu.2019.03052." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235. 10.3390/jcm10112235.
</cite> [<a href="https://doi.org/10.3390/jcm10112235" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8196750/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34064035/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dresser%20L,%20Wlodarski%20R,%20Rezania%20K,%20Soliven%20B.%20Myasthenia%20gravis:%20epidemiology,%20pathophysiology%20and%20clinical%20manifestations.%20J%20Clin%20Med.%202021;10(11):2235.%2010.3390/jcm10112235." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Huijbers MG, Zhang W, Klooster R, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci U S A. 2013;110(51):20783–8. 10.1073/pnas.1313944110.
</cite> [<a href="https://doi.org/10.1073/pnas.1313944110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3870730/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24297891/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huijbers%20MG,%20Zhang%20W,%20Klooster%20R,%20et%20al.%20MuSK%20IgG4%20autoantibodies%20cause%20myasthenia%20gravis%20by%20inhibiting%20binding%20between%20MuSK%20and%20Lrp4.%20Proc%20Natl%20Acad%20Sci%20U%20S%20A.%202013;110(51):20783%E2%80%938.%2010.1073/pnas.1313944110." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Vaccaro C, Zhou J, Ober RJ, Ward ES. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005;23(10):1283–8. 10.1038/nbt1143.
</cite> [<a href="https://doi.org/10.1038/nbt1143" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16186811/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vaccaro%20C,%20Zhou%20J,%20Ober%20RJ,%20Ward%20ES.%20Engineering%20the%20Fc%20region%20of%20immunoglobulin%20G%20to%20modulate%20in%20vivo%20antibody%20levels.%20Nat%20Biotechnol.%202005;23(10):1283%E2%80%938.%2010.1038/nbt1143." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372–86. 10.1172/JCI97911.
</cite> [<a href="https://doi.org/10.1172/JCI97911" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6159959/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30040076/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ulrichts%20P,%20Guglietta%20A,%20Dreier%20T,%20et%20al.%20Neonatal%20Fc%20receptor%20antagonist%20efgartigimod%20safely%20and%20sustainably%20reduces%20IgGs%20in%20humans.%20J%20Clin%20Invest.%202018;128(10):4372%E2%80%9386.%2010.1172/JCI97911." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Heo YA. Efgartigimod: first approval. Drugs. 2022;82(3):341–8. 10.1007/s40265-022-01678-3.
</cite> [<a href="https://doi.org/10.1007/s40265-022-01678-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8855644/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35179720/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Heo%20YA.%20Efgartigimod:%20first%20approval.%20Drugs.%202022;82(3):341%E2%80%938.%2010.1007/s40265-022-01678-3." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526–36. 10.1016/S1474-4422(21)00159-9.
</cite> [<a href="https://doi.org/10.1016/S1474-4422(21)00159-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34146511/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Howard%20JF,%20Bril%20V,%20Vu%20T,%20et%20al.%20Safety,%20efficacy,%20and%20tolerability%20of%20efgartigimod%20in%20patients%20with%20generalised%20myasthenia%20gravis%20(ADAPT):%20a%20multicentre,%20randomised,%20placebo-controlled,%20phase%203%20trial.%20Lancet%20Neurol.%202021;20(7):526%E2%80%9336.%2010.1016/S1474-4422(21)00159-9." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Bril V, Burns TM, Mantegazza R, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019. 10.1212/WNL.0000000000007600.
</cite> [<a href="https://doi.org/10.1212/WNL.0000000000007600" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6556100/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31118245/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bril%20V,%20Burns%20TM,%20Mantegazza%20R,%20et%20al.%20Randomized%20phase%202%20study%20of%20FcRn%20antagonist%20efgartigimod%20in%20generalized%20myasthenia%20gravis.%20Neurology.%202019.%2010.1212/WNL.0000000000007600." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. 10.1136/bmj.b2700.
</cite> [<a href="https://doi.org/10.1136/bmj.b2700" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2714672/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19622552/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liberati%20A,%20Altman%20DG,%20Tetzlaff%20J,%20et%20al.%20The%20PRISMA%20statement%20for%20reporting%20systematic%20reviews%20and%20meta-analyses%20of%20studies%20that%20evaluate%20healthcare%20interventions:%20explanation%20and%20elaboration.%20BMJ.%202009;339:b2700.%2010.1136/bmj.b2700." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487–9. 10.1212/wnl.52.7.1487.
</cite> [<a href="https://doi.org/10.1212/wnl.52.7.1487" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10227640/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wolfe%20GI,%20Herbelin%20L,%20Nations%20SP,%20Foster%20B,%20Bryan%20WW,%20Barohn%20RJ.%20Myasthenia%20gravis%20activities%20of%20daily%20living%20profile.%20Neurology.%201999;52(7):1487%E2%80%939.%2010.1212/wnl.52.7.1487." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–6. 10.1046/j.1445-2197.2003.02748.x.
</cite> [<a href="https://doi.org/10.1046/j.1445-2197.2003.02748.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12956787/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Slim%20K,%20Nini%20E,%20Forestier%20D,%20Kwiatkowski%20F,%20Panis%20Y,%20Chipponi%20J.%20Methodological%20index%20for%20non-randomized%20studies%20(minors):%20development%20and%20validation%20of%20a%20new%20instrument.%20ANZ%20J%20Surg.%202003;73(9):712%E2%80%936.%2010.1046/j.1445-2197.2003.02748.x." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. 10.1136/bmj.i4919.
</cite> [<a href="https://doi.org/10.1136/bmj.i4919" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5062054/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27733354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sterne%20JA,%20Hern%C3%A1n%20MA,%20Reeves%20BC,%20et%20al.%20ROBINS-I:%20a%20tool%20for%20assessing%20risk%20of%20bias%20in%20non-randomised%20studies%20of%20interventions.%20BMJ.%202016;355:i4919.%2010.1136/bmj.i4919." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Luo S, Jiang Q, Zeng W, et al. Efgartigimod for generalized myasthenia gravis: a multicenter real-world cohort study in China. Ann Clin Transl Neurol. 2024;11(8):2212–21. 10.1002/acn3.52142.
</cite> [<a href="https://doi.org/10.1002/acn3.52142" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11330228/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38973109/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Luo%20S,%20Jiang%20Q,%20Zeng%20W,%20et%20al.%20Efgartigimod%20for%20generalized%20myasthenia%20gravis:%20a%20multicenter%20real-world%20cohort%20study%20in%20China.%20Ann%20Clin%20Transl%20Neurol.%202024;11(8):2212%E2%80%9321.%2010.1002/acn3.52142." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Song J, Wang H, Huan X, et al. Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series. Front Immunol. 2024. 10.3389/fimmu.2024.1418503.
</cite> [<a href="https://doi.org/10.3389/fimmu.2024.1418503" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11317420/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39136012/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Song%20J,%20Wang%20H,%20Huan%20X,%20et%20al.%20Efgartigimod%20as%20a%20promising%20add-on%20therapy%20for%20myasthenic%20crisis:%20a%20prospective%20case%20series.%20Front%20Immunol.%202024.%2010.3389/fimmu.2024.1418503." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Frangiamore R, Rinaldi E, Vanoli F, et al. Efgartigimod in generalized myasthenia gravis: a real-life experience at a national reference center. Eur J Neurol. 2024;31(4):e16189. 10.1111/ene.16189.
</cite> [<a href="https://doi.org/10.1111/ene.16189" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11236067/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38164996/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Frangiamore%20R,%20Rinaldi%20E,%20Vanoli%20F,%20et%20al.%20Efgartigimod%20in%20generalized%20myasthenia%20gravis:%20a%20real-life%20experience%20at%20a%20national%20reference%20center.%20Eur%20J%20Neurol.%202024;31(4):e16189.%2010.1111/ene.16189." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Remijn-Nelissen L, Tannemaat MR, Ruiter AM, Campman YJM, Verschuuren JJGM. Efgartigimod in refractory autoimmune myasthenia gravis. Muscle Nerve. 2024;70(3):325–32. 10.1002/mus.28184.
</cite> [<a href="https://doi.org/10.1002/mus.28184" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38899431/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Remijn-Nelissen%20L,%20Tannemaat%20MR,%20Ruiter%20AM,%20Campman%20YJM,%20Verschuuren%20JJGM.%20Efgartigimod%20in%20refractory%20autoimmune%20myasthenia%20gravis.%20Muscle%20Nerve.%202024;70(3):325%E2%80%9332.%2010.1002/mus.28184." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Wang P, Zhang B, Yin J, et al. Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients. Front Neurol. 2024. 10.3389/fneur.2024.1407418.
</cite> [<a href="https://doi.org/10.3389/fneur.2024.1407418" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11222781/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38966082/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20P,%20Zhang%20B,%20Yin%20J,%20et%20al.%20Prospective%20cohort%20study%20evaluating%20efficacy%20and%20safety%20of%20efgartigimod%20in%20Chinese%20generalized%20myasthenia%20gravis%20patients.%20Front%20Neurol.%202024.%2010.3389/fneur.2024.1407418." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Fuchs L, Shelly S, Vigiser I, et al. Real-world experience with efgartigimod in patients with myasthenia gravis. J Neurol. 2024;271(6):3462–70. 10.1007/s00415-024-12293-5.
</cite> [<a href="https://doi.org/10.1007/s00415-024-12293-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38528163/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fuchs%20L,%20Shelly%20S,%20Vigiser%20I,%20et%20al.%20Real-world%20experience%20with%20efgartigimod%20in%20patients%20with%20myasthenia%20gravis.%20J%20Neurol.%202024;271(6):3462%E2%80%9370.%2010.1007/s00415-024-12293-5." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Horiuchi K, Nakamura S, Yamada K, Inoue T, Oiwa K. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series. Neuromuscul Disord. 2024;39:37–41. 10.1016/j.nmd.2024.04.005.
</cite> [<a href="https://doi.org/10.1016/j.nmd.2024.04.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38772072/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Horiuchi%20K,%20Nakamura%20S,%20Yamada%20K,%20Inoue%20T,%20Oiwa%20K.%20Retrospective%20analysis%20of%20efgartigimod%20use%20in%20patients%20with%20double-seronegative%20generalized%20myasthenia%20gravis:%20a%20case%20series.%20Neuromuscul%20Disord.%202024;39:37%E2%80%9341.%2010.1016/j.nmd.2024.04.005." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Katyal N, Halldorsdottir K, Govindarajan R, et al. Safety and outcomes with efgartigimod use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Muscle Nerve. 2023;68(5):762–6. 10.1002/mus.27974.
</cite> [<a href="https://doi.org/10.1002/mus.27974" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37695277/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Katyal%20N,%20Halldorsdottir%20K,%20Govindarajan%20R,%20et%20al.%20Safety%20and%20outcomes%20with%20efgartigimod%20use%20for%20acetylcholine%20receptor-positive%20generalized%20myasthenia%20gravis%20in%20clinical%20practice.%20Muscle%20Nerve.%202023;68(5):762%E2%80%936.%2010.1002/mus.27974." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Kaminski HJ, Denk J. Corticosteroid treatment-resistance in myasthenia gravis. Front Neurol. 2022;13:886625. 10.3389/fneur.2022.886625.
</cite> [<a href="https://doi.org/10.3389/fneur.2022.886625" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9083070/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35547366/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kaminski%20HJ,%20Denk%20J.%20Corticosteroid%20treatment-resistance%20in%20myasthenia%20gravis.%20Front%20Neurol.%202022;13:886625.%2010.3389/fneur.2022.886625." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Antonini G, Habetswallner F, Inghilleri M, et al. Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy. Heliyon. 2023;9(6):e16367. 10.1016/j.heliyon.2023.e16367.
</cite> [<a href="https://doi.org/10.1016/j.heliyon.2023.e16367" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10238888/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37274644/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Antonini%20G,%20Habetswallner%20F,%20Inghilleri%20M,%20et%20al.%20Real%20world%20study%20on%20prevalence,%20treatment%20and%20economic%20burden%20of%20myasthenia%20gravis%20in%20Italy.%20Heliyon.%202023;9(6):e16367.%2010.1016/j.heliyon.2023.e16367." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol. 2016 Apr;263(4):826-34. doi: 10.1007/s00415-015-7963-5. Epub 2015 Dec 24. PMID: 26705120; PMCID: PMC4826656.</cite> [<a href="https://doi.org/10.1007/s00415-015-7963-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4826656/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26705120/" class="usa-link">PubMed</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Howard JF, Bril V, Vu T, et al. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. Front Neurol. 2023;14:1284444. 10.3389/fneur.2023.1284444.
</cite> [<a href="https://doi.org/10.3389/fneur.2023.1284444" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10842202/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38318236/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Howard%20JF,%20Bril%20V,%20Vu%20T,%20et%20al.%20Long-term%20safety,%20tolerability,%20and%20efficacy%20of%20efgartigimod%20(ADAPT+):%20interim%20results%20from%20a%20phase%203%20open-label%20extension%20study%20in%20participants%20with%20generalized%20myasthenia%20gravis.%20Front%20Neurol.%202023;14:1284444.%2010.3389/fneur.2023.1284444." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Vakrakou AG, Karachaliou E, Chroni E, et al. Immunotherapies in MuSK-positive myasthenia gravis; an IgG4 antibody-mediated disease. Front Immunol. 2023. 10.3389/fimmu.2023.1212757.
</cite> [<a href="https://doi.org/10.3389/fimmu.2023.1212757" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10410455/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37564637/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vakrakou%20AG,%20Karachaliou%20E,%20Chroni%20E,%20et%20al.%20Immunotherapies%20in%20MuSK-positive%20myasthenia%20gravis;%20an%20IgG4%20antibody-mediated%20disease.%20Front%20Immunol.%202023.%2010.3389/fimmu.2023.1212757." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest. 2018;128(10):4372–86. 10.1172/JCI97911.
</cite> [<a href="https://doi.org/10.1172/JCI97911" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6159959/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30040076/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ulrichts%20P,%20Guglietta%20A,%20Dreier%20T,%20et%20al.%20Neonatal%20Fc%20receptor%20antagonist%20efgartigimod%20safely%20and%20sustainably%20reduces%20IgGs%20in%20humans.%20J%20Clin%20Invest.%202018;128(10):4372%E2%80%9386.%2010.1172/JCI97911." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Zhu G, Ma Y, Zhou H, et al. Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod. Front Immunol. 2024. 10.3389/fimmu.2024.1401972.
</cite> [<a href="https://doi.org/10.3389/fimmu.2024.1401972" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11190065/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38911858/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu%20G,%20Ma%20Y,%20Zhou%20H,%20et%20al.%20Case%20report:%20Rapid%20clinical%20improvement%20in%20acute%20exacerbation%20of%20MuSK-MG%20with%20efgartigimod.%20Front%20Immunol.%202024.%2010.3389/fimmu.2024.1401972." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Horiuchi K, Nakamura S, Yamada K, Inoue T, Oiwa K. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series. Neuromuscul Disord. 2024;39:37–41. 10.1016/j.nmd.2024.04.005.
</cite> [<a href="https://doi.org/10.1016/j.nmd.2024.04.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38772072/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Horiuchi%20K,%20Nakamura%20S,%20Yamada%20K,%20Inoue%20T,%20Oiwa%20K.%20Retrospective%20analysis%20of%20efgartigimod%20use%20in%20patients%20with%20double-seronegative%20generalized%20myasthenia%20gravis:%20a%20case%20series.%20Neuromuscul%20Disord.%202024;39:37%E2%80%9341.%2010.1016/j.nmd.2024.04.005." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>Chen X, Qiu J, Gao Z, et al. Myasthenia gravis: molecular mechanisms and promising therapeutic strategies. Biochem Pharmacol. 2023;218:115872. 10.1016/j.bcp.2023.115872.
</cite> [<a href="https://doi.org/10.1016/j.bcp.2023.115872" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37865142/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20X,%20Qiu%20J,%20Gao%20Z,%20et%20al.%20Myasthenia%20gravis:%20molecular%20mechanisms%20and%20promising%20therapeutic%20strategies.%20Biochem%20Pharmacol.%202023;218:115872.%2010.1016/j.bcp.2023.115872." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Nelke C, Schroeter CB, Barman S, et al. Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clustering. eBioMedicine. 2024;105:105231. 10.1016/j.ebiom.2024.105231.
</cite> [<a href="https://doi.org/10.1016/j.ebiom.2024.105231" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11269806/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38959848/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nelke%20C,%20Schroeter%20CB,%20Barman%20S,%20et%20al.%20Identification%20of%20disease%20phenotypes%20in%20acetylcholine%20receptor-antibody%20myasthenia%20gravis%20using%20proteomics-based%20consensus%20clustering.%20eBioMedicine.%202024;105:105231.%2010.1016/j.ebiom.2024.105231." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Zhao R, Luo S, Zhao C. The role of innate immunity in myasthenia gravis. Autoimmun Rev. 2021;20(5):102800. 10.1016/j.autrev.2021.102800.
</cite> [<a href="https://doi.org/10.1016/j.autrev.2021.102800" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33722749/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhao%20R,%20Luo%20S,%20Zhao%20C.%20The%20role%20of%20innate%20immunity%20in%20myasthenia%20gravis.%20Autoimmun%20Rev.%202021;20(5):102800.%2010.1016/j.autrev.2021.102800." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Sriwastava S, Tandon M, Kataria S, Daimee M, Sultan S. New onset of ocular myasthenia gravis in a patient with COVID-19: a novel case report and literature review. J Neurol. 2021;268(8):2690–6. 10.1007/s00415-020-10263-1.
</cite> [<a href="https://doi.org/10.1007/s00415-020-10263-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7549728/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33047223/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sriwastava%20S,%20Tandon%20M,%20Kataria%20S,%20Daimee%20M,%20Sultan%20S.%20New%20onset%20of%20ocular%20myasthenia%20gravis%20in%20a%20patient%20with%20COVID-19:%20a%20novel%20case%20report%20and%20literature%20review.%20J%20Neurol.%202021;268(8):2690%E2%80%936.%2010.1007/s00415-020-10263-1." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Ströbel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev. 2013;12(9):875–84. 10.1016/j.autrev.2013.03.007.
</cite> [<a href="https://doi.org/10.1016/j.autrev.2013.03.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23535159/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Marx%20A,%20Pfister%20F,%20Schalke%20B,%20Saruhan-Direskeneli%20G,%20Melms%20A,%20Str%C3%B6bel%20P.%20The%20different%20roles%20of%20the%20thymus%20in%20the%20pathogenesis%20of%20the%20various%20myasthenia%20gravis%20subtypes.%20Autoimmun%20Rev.%202013;12(9):875%E2%80%9384.%2010.1016/j.autrev.2013.03.007." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Sims GP, Shiono H, Willcox N, Stott DI. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol Baltim Md 1950. 2001;167(4):1935–44. 10.4049/jimmunol.167.4.1935.</cite> [<a href="https://doi.org/10.4049/jimmunol.167.4.1935" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11489973/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sims%20GP,%20Shiono%20H,%20Willcox%20N,%20Stott%20DI.%20Somatic%20hypermutation%20and%20selection%20of%20B%20cells%20in%20thymic%20germinal%20centers%20responding%20to%20acetylcholine%20receptor%20in%20myasthenia%20gravis.%20J%20Immunol%20Baltim%20Md%201950.%202001;167(4):1935%E2%80%9344.%2010.4049/jimmunol.167.4.1935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Zografou C, Vakrakou AG, Stathopoulos P. Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders. Front Immunol. 2021;12:686466. 10.3389/fimmu.2021.686466.
</cite> [<a href="https://doi.org/10.3389/fimmu.2021.686466" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8248361/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34220839/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zografou%20C,%20Vakrakou%20AG,%20Stathopoulos%20P.%20Short-%20and%20long-lived%20autoantibody-secreting%20cells%20in%20autoimmune%20neurological%20disorders.%20Front%20Immunol.%202021;12:686466.%2010.3389/fimmu.2021.686466." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Feferman T, Maiti PK, Berrih-Aknin S, Bismuth J, Bidault J, Fuchs S, Souroujon MC. Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J Immunol. 2005 May 1;174(9):5324-31. doi: 10.4049/jimmunol.174.9.5324. PMID: 15843529. 10.4049/jimmunol.174.9.5324</cite> [<a href="https://doi.org/10.4049/jimmunol.174.9.5324" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15843529/" class="usa-link">PubMed</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Uzawa A, Kuwabara S, Suzuki S, et al. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021;203(3):366–74. 10.1111/cei.13546.
</cite> [<a href="https://doi.org/10.1111/cei.13546" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7874834/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33184844/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Uzawa%20A,%20Kuwabara%20S,%20Suzuki%20S,%20et%20al.%20Roles%20of%20cytokines%20and%20T%20cells%20in%20the%20pathogenesis%20of%20myasthenia%20gravis.%20Clin%20Exp%20Immunol.%202021;203(3):366%E2%80%9374.%2010.1111/cei.13546." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Zhou Y, Jiang S. Roles of FcRn in antigen-presenting cells during autoimmunity and a clinical evaluation of efgartigimod as an FcRn blocker. Pathogens. 2023. 10.3390/pathogens12060817.
</cite> [<a href="https://doi.org/10.3390/pathogens12060817" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10303165/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37375507/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhou%20Y,%20Jiang%20S.%20Roles%20of%20FcRn%20in%20antigen-presenting%20cells%20during%20autoimmunity%20and%20a%20clinical%20evaluation%20of%20efgartigimod%20as%20an%20FcRn%20blocker.%20Pathogens.%202023.%2010.3390/pathogens12060817." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Qian S, Zhang D, Yang Z, et al. The role of immunoglobulin transport receptor, neonatal Fc receptor in mucosal infection and immunity and therapeutic intervention. Int Immunopharmacol. 2024;138:112583. 10.1016/j.intimp.2024.112583.
</cite> [<a href="https://doi.org/10.1016/j.intimp.2024.112583" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38971109/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qian%20S,%20Zhang%20D,%20Yang%20Z,%20et%20al.%20The%20role%20of%20immunoglobulin%20transport%20receptor,%20neonatal%20Fc%20receptor%20in%20mucosal%20infection%20and%20immunity%20and%20therapeutic%20intervention.%20Int%20Immunopharmacol.%202024;138:112583.%2010.1016/j.intimp.2024.112583." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865–87. 10.1007/s40265-022-01726-y.
</cite> [<a href="https://doi.org/10.1007/s40265-022-01726-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9152838/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35639288/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Menon%20D,%20Bril%20V.%20Pharmacotherapy%20of%20generalized%20myasthenia%20gravis%20with%20special%20emphasis%20on%20newer%20biologicals.%20Drugs.%202022;82(8):865%E2%80%9387.%2010.1007/s40265-022-01726-y." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Kaminski HJ, Denk J. Corticosteroid treatment-resistance in myasthenia gravis. Front Neurol. 2022;13:886625. 10.3389/fneur.2022.886625.
</cite> [<a href="https://doi.org/10.3389/fneur.2022.886625" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9083070/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35547366/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kaminski%20HJ,%20Denk%20J.%20Corticosteroid%20treatment-resistance%20in%20myasthenia%20gravis.%20Front%20Neurol.%202022;13:886625.%2010.3389/fneur.2022.886625." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Goronzy JJ, Weyand CM. Immune aging and autoimmunity. Cell Mol Life Sci. 2012;69(10):1615–23. 10.1007/s00018-012-0970-0.
</cite> [<a href="https://doi.org/10.1007/s00018-012-0970-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4277694/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22466672/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Goronzy%20JJ,%20Weyand%20CM.%20Immune%20aging%20and%20autoimmunity.%20Cell%20Mol%20Life%20Sci.%202012;69(10):1615%E2%80%9323.%2010.1007/s00018-012-0970-0." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366048/bin/40001_2025_3057_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">Additional file1</a><sup> (872.5KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>No datasets were generated or analysed during the current study.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from European Journal of Medical Research are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s40001-025-03057-6"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/40001_2025_Article_3057.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (2.6 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12366048/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12366048/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366048%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366048/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12366048/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12366048/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40830529/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12366048/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40830529/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12366048/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12366048/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="m9ExVnd22GkqGZ0j45bdHS2RNwgjm7eAzyyM2OQFOVNGWHBvvcNTh1YdzXJj5ATB">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
        <script type="module" crossorigin="" src="/static/assets/math-574fdcc6.js"></script>
    
    

    </body>
</html>
